Are biologics safe in the treatment of atopic dermatitis? A review with a focus on immediate hypersensitivity reactions - 07/08/11
Abstract |
Traditional systemic agents used for the treatment of atopic dermatitis (AD) are associated with significant potential toxicities and often do not provide adequate therapeutic responses. Biologic agents hold promise for a more targeted and less toxic approach to AD systemic therapy. Patients with AD, however, may theoretically be at higher risk of developing IgE-mediated reactions to protein-based therapies. We performed a review of publications reporting the use of biologics in the treatment of AD. Of the 261 patients with AD identified who were exposed to a biologic therapy, no type-I immediate hypersensitivity reactions were reported. One infusion reaction occurred with infliximab and two patients had “mild respiratory difficulty” with interferon-gamma. Thrombocytopenia may occur at a higher rate than expected in patients treated with efalizumab. Combined, these data support the safety of biologics in the treatment of AD and the further development of new biologics for this population should be encouraged.
Le texte complet de cet article est disponible en PDF.Key words : atopic dermatitis, biologics, immediate hypersensitivity reactions
Abbreviations used : AD, EASI, IL, TNF
Plan
Supported by the Oregon Clinical and Translational Research Institute, grant No. UL1 RR024140 from the National Center for Research Resources, a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. |
|
Conflicts of interest: None declared. |
Vol 61 - N° 4
P. 666-676 - octobre 2009 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?